{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-028046","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.156844+00:00","generated_at":"2026-05-15T11:52:54.777458+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aprea Therapeutics reports FY2025 net loss of $12.6M; APR-1051 shows two partial responses","bullets":["Cash and equivalents $14.6M at Dec 31, 2025; plus Jan 2026 private placement of $5.6M funds operations into Q1 2027.","Net loss $12.6M ($1.93/share) for FY2025 vs $13.0M ($2.35/share) in FY2024; R&D spend down to $7.0M from $9.4M.","APR-1051 (WEE1 inhibitor) yields two unconfirmed partial responses in PPP2R1A-mutated endometrial cancer; dose escalation ongoing at 220 mg.","ATRN-119 (ATR inhibitor) RP2D set at 1,100 mg; monotherapy enrollment paused, exploring combination studies.","Appointed Eugene Kennedy, MD, as Chief Medical Advisor in February 2026 to support next phase of development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-028046","json":"https://secwatch.observer/filing/0001104659-26-028046.json","markdown":"https://secwatch.observer/filing/0001104659-26-028046.md","text":"https://secwatch.observer/filing/0001104659-26-028046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926028046/0001104659-26-028046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926028046/apre-20260316x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:52:54.777458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb833883b12930f3ea9a0dc8f37517f7b7b36c29","claim":"Aprea Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.","evidence_excerpt":"On March 16, 2026, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926028046/0001104659-26-028046-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}